MXCT.L - MaxCyte, Inc.
| Previous close | 332.50 |
| Open | 0.00 |
| Bid | 320.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 42,607 |
| Market cap | 334.916M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.24 |
| Earnings date | 10 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.50 |
Simply Wall St.Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- Simply Wall St.
Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive
MaxCyte, Inc. ( LON:MXCT ) shareholders that were waiting for something to happen have been dealt a blow with a 28...
ZacksMaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year
Viewing insider transactions for MaxCyte, Inc.'s ( LON:MXCT ) over the last year, we see that insiders were net buyers...
- Simply Wall St.
The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- Simply Wall St.
MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021)
MaxCyte ( LON:MXCT ) Full Year 2022 Results Key Financial Results Revenue: US$44.3m (up 31% from FY 2021). Net loss...
- Simply Wall St.
A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress
Every investor in MaxCyte, Inc. ( LON:MXCT ) should be aware of the most powerful shareholder groups. The group holding...
ZacksMaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Simply Wall St.
MaxCyte (LON:MXCT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Zacks
MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade
MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m
Insiders who acquired US$166k worth of MaxCyte, Inc.'s ( LON:MXCT ) stock at an average price of US$8.29 in the past 12...
ZacksMaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
MaxCyte (LON:MXCT) shareholders have earned a 65% CAGR over the last three years
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Not every pick can be a...
ZacksMaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last?
MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Simply Wall St.
With 69% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns
If you want to know who really controls MaxCyte, Inc. ( LON:MXCT ), then you'll have to look at the makeup of its share...
Motley FoolMaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript
Good day, and thank you for standing by, and welcome to MaxCyte second quarter 2022 earnings conference call. My name is Sean Menarguez, and I'm the director of investor relations here at MaxCyte. On the call from MaxCyte, we have Doug Doerfler, president and chief executive officer; and Ron Holtz, interim chief financial officer.
ZacksMaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 6.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
